Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cell Therapy for HIV Immune Reconstitution
NCT03240328Phase 1Recruiting
- Sponsor
- Guangzhou Eighth People's Hospital
- Start
- Oct 2017
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of VC-CAR-T in human immunodeficiency virus infection (HIV), sponsored by Guangzhou Eighth People's Hospital. Primary endpoint: Incidence of treatment-associated adverse events at 6 months. Started Oct 2017; status: recruiting.
02
Drugs
VC-CAR-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03240328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240328.